It’s Still Early: See Why (MAIA) Is Topping Our Pre-Market Watchlist Right Now

*Sponsored Krypton Street Announces MAIA Biotechnology (NYSE: MAIA) As Its Next Potential Breakout Idea For Monday, January 13th, 2025! And Here’s Why… Bullish Technical Signals: Late Friday night (MAIA) triggered 14 Bullish Signals on TradingView, including the Momentum Indicator, underscoring strong near-term potential. High-Value Markets: Targeting NSCLC ($34B), CRC ($20B), HCC ($3B), and SCLC ($2B), MAIA addresses key areas in oncology. Analyst Targets: Noble Capital’s $14.00 target suggests 573% upside potential; Diamond Equity’s $11.25 target suggests 440% upside potential. Intellectual Property: Five patents and 29 pending applications  protect (MAIA)’s innovations through 2041. January 13, 2025 Dear Reader, It’s still early but I wanted to make sure you saw this. After Friday’s biotech moved approximately 81% before the bell even rang, we’re now turning our attention to another one. The biotech industry stands out as a rare sector where small, single-product companies can transform tiny market caps into massive ones almost overnight. Take MAIA Biotechnology (NYSE: MAIA), for example. Robert LeBoyer, Senior Vice President and Biotechnology Equity Research Analyst at Noble Capital Markets, has set a $14.00 target, pointing to a potential 573% upside from Friday’s opening of $2.08. And he’s not alone.  Diamond Equity Research also issued a bullish target of $11.25, suggesting a 440% upside. The excitement doesn’t stop there.  By late Friday night, around 7:48 PM EST in after-hours trading, (MAIA) appeared to be firing on all cylinders, triggering 14 Bullish Signals on TradingView’s technical analysis tool, including the coveted Momentum Indicator on the 5-minute time frame. But that’s not the only reason MAIA Biotechnology (NYSE: MAIA) is dominating the conversation.  Starting today, Dr. Vlad Vitoc, CEO of MAIA Biotechnology (NYSE: MAIA), is set to present at Biotech Showcase™ 2025 in San Francisco, one of the industry’s most anticipated conferences.  During the presentation, Dr. Vitoc will unveil key updates on (MAIA)’s pivotal THIO-101 Phase 2 expansion trial, which focuses on advanced non-small cell lung cancer (NSCLC) patients receiving third-line (3L) therapy. He will also provide insights into (MAIA)’s plans for upcoming trials targeting multiple cancer indications, underscoring the company’s focus on addressing unmet needs in the global oncology market. That’s why MAIA Biotechnology (NYSE: MAIA) is at the top of our watchlist this morning. There’s plenty I could say about this company, but let me start with one word: Cancer. It’s the dreaded diagnosis that no one wants, yet countless individuals confront every year.  But MAIA Biotechnology (NYSE: MAIA) is fearlessly stepping into the arena with a weapon unlike anything we’ve seen before: telomere-targeting immunotherapies.  If you haven’t heard of (MAIA) yet, consider this your wake-up call.  This company isn’t just playing in the biotech sandbox—it’s rewriting the rules of the game. A Game-Changer in Cancer Treatment MAIA’s lead asset, THIO (6-thio-dG), is the first and only telomere-targeting agent in clinical development.  THIO operates with a dual mechanism of action (MoA): directly targeting telomeres to disrupt cancer cell replication while simultaneously activating an immune response to destroy the cancer cells. The Phase 2 THIO-101 trial focuses on non-small cell lung cancer (NSCLC), a market worth a staggering $34B annually.  Results? Nothing short of groundbreaking.  THIO followed by immune checkpoint inhibitors (ICIs) like Regeneron’s Libtayo® has demonstrated 60% complete response rates in preclinical models.  Patients achieved sustained remission after just two cycles of therapy, with no cancer recurrence—even after rechallenge with 5x the initial cancer cell load.  This isn’t just a treatment—it’s a potential revolution. Market Potential: Unmet Needs, Unrivaled Potential Cancer treatments are a high-stakes game, and (MAIA) is targeting the jackpot. NSCLC is the largest cancer market globally, and THIO is positioned to address patients who have become resistant to current checkpoint inhibitors—an enormous unmet need.  The U.S. FDA has already recognized THIO’s promise, granting Orphan Designations for small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and glioblastoma (brain cancer). Let’s talk numbers: NSCLC: $34B annual sales. Checkpoint Inhibitors: $46B global market in 2023, with Keytruda alone generating $9B in NSCLC sales. HCC and SCLC: Combined annual sales of $5B with massive growth potential. MAIA Biotechnology (NYSE: MAIA) owns worldwide rights to THIO, securing the company’s stake in every dollar these markets generate. THIO-101: A Masterclass in Efficacy The THIO-101 trial has set a new standard for cancer therapies. Patients treated with THIO + Libtayo® showed a disease control rate (DCR) of 85%, far surpassing the 25–35% DCR achieved by traditional chemotherapy.  Even in third-line (3L) settings—where options are typically grim—THIO delivered unprecedented outcomes: Median progression-free survival (PFS): 2.5 months (compared to 1.5 months with chemotherapy). Median overall survival (OS): 5.8 months (nearly double the historical benchmark). Objective response rate (ORR): 38%, a dramatic leap from the 6–10% seen with chemotherapy. These results underscore one thing: THIO is not just effective; it’s transformative. Building the Pipeline: (MAIA)’s Vision for the Future (MAIA) isn’t stopping at NSCLC. With a robust pipeline of trials planned for colorectal cancer (CRC), SCLC, HCC, and other solid tumors, the company is poised to address multiple high-value cancer indications.  Interestingly, preclinical models in CRC demonstrated a 100% complete response rate with long-term immune memory formation. The strategy?  Expand THIO’s applications while leveraging collaborations with big pharma players like Regeneron.  MAIA Biotechnology (NYSE: MAIA) Expands Collaboration with Regeneron, a +$76B Industry Leader Less than six weeks ago, on December 3, 2024, MAIA Biotechnology (NYSE: MAIA) announced the expansion of its clinical supply agreement with Regeneron, a +$76B industry leader, for the ongoing Phase 2 THIO-101 trial.  This partnership focuses on evaluating MAIA's lead asset, THIO, in combination with Regeneron’s Libtayo® (cemiplimab), an immune checkpoint inhibitor.  The trial targets advanced non-small cell lung cancer (NSCLC) patients resistant to prior checkpoint inhibitor therapies and chemotherapy. Initially signed in 2021, the agreement was designed to supply Libtayo® during the dose selection and safety evaluation stages.  The expanded agreement now supports a broader patient population to assess THIO’s efficacy at the optimal dose. Regeneron provides Libtayo® for all trial patients, while MAIA sponsors the study and retains exclusive global rights to develop and commercialize THIO. This collaboration highlights Regeneron's confidence in THIO’s potential to enhance checkpoint inhibitor outcomes.  With THIO demonstrating promising disease control, progression-free survival, and overall response rates, MAIA Biotechnology (NYSE: MAIA) is advancing its regulatory pathway and exploring the potential for accelerated U.S. approval based on trial results.  Beyond the expansion of THIO-101, the company is systematically building a robust pipeline of Phase 2/3 trials, including THIO-102 (targeting CRC, HCC, and SCLC) and THIO-103 (first-line NSCLC).  Together, these initiatives position MAIA as a biotech powerhouse with a portfolio designed for long-term growth. Intellectual Property: Locking in the Advantage (MAIA)’s intellectual property portfolio is as robust as its science. The company holds five issued patents and 29 pending applications covering telomere-targeting compounds and THIO’s immunogenic treatment strategy.  With exclusivity agreements extending to 2041, MAIA is ensuring its technology remains unrivaled for decades. Leadership: Experience That Delivers MAIA Biotechnology (NYSE: MAIA)’s  team brings over 70 years of combined experience in oncology and biotech.  CEO Dr. Vlad Vitoc has led the launch of 12 oncology compounds across 20 tumor types, while CSO Dr. Sergei Gryaznov—the co-inventor of THIO—is a global authority on telomeres and cancer. This isn’t their first rodeo, and it shows. The Bottom Line MAIA Biotechnology (NYSE: MAIA) is not just another biotech company. It’s a disruptor, a trailblazer, and quite possibly the future of cancer treatment.  With a pipeline brimming with potential, collaborations with leading industry players, and a market valued in the high ranges, (MAIA) stands out as a company to keep on your radar. In the fight against cancer, (MAIA) is bringing the big guns.  And if their data is anything to go by, this is one company to keep an eye on. 7 Reasons Why MAIA Biotechnology (NYSE: MAIA) is Topping Our Early Morning Watchlist This Monday… 1. Tackling High-Value Markets: MAIA is targeting NSCLC ($34B), colorectal cancer ($20B), and liver cancer ($3B), among the largest and most critical areas in oncology. 2. Analyst Targets: Robert LeBoyer of Noble Capital Markets set a $14.00 target (573% upside), while Diamond Equity Research issued a similarly bullish $11.25 target (440% upside). 3. Bullish Technical Signals: MAIA recently triggered 14 Bullish Signals on TradingView, including the Momentum Indicator, underscoring strong near-term market activity. 4. Unique Science in Action: THIO is the first telomere-targeting agent in clinical development, leveraging a dual mechanism to disrupt cancer replication and spark an immune response. 5. Results That Outperform: THIO achieves an 85% disease control rate and a 38% objective response rate, outperforming traditional late-stage cancer treatments. 6. Industry Spotlight: CEO Dr. Vlad Vitoc is presenting pivotal updates and future plans at Biotech Showcase™ 2025, a premier industry event. 7. Strength in Intellectual Property: With five patents and 29 pending applications, MAIA secures exclusivity on its innovations through 2041, ensuring long-term leadership. Consider Putting MAIA Biotechnology (NYSE: MAIA) On  Your Radar This Week… MAIA Biotechnology isn’t just entering the oncology market—it’s poised to transform it.  With an analyst target suggesting 573% in upside upside potential, there’s plenty of reasons to take a closer look at this one. Targeting markets valued at $34B (NSCLC), $20B (CRC), $3B (HCC), and $2B (SCLC), (MAIA) is laser-focused on tackling the cancers that matter most. But this isn’t just about big markets; it’s about revolutionary science. THIO, the first telomere-targeting agent in clinical development, is delivering results that surpass conventional therapies—a remarkable 85% disease control rate and a 38% objective response rate in late-stage patients prove that this isn’t just a treatment; it’s a breakthrough. With Dr. Vlad Vitoc scheduled to present updates at Biotech Showcase™ 2025 and an intellectual property portfolio securing exclusivity through 2041, (MAIA) is positioning itself for long-term success. THIO’s demonstrated ability to enhance checkpoint inhibitors, combined with the company’s focus on a $46B industry, highlights its potential to thrive in the rapidly evolving oncology landscape. The verdict is in: MAIA Biotechnology (NYSE: MAIA) isn’t just another biotech story—it’s one little-known company to keep an eye on today. We have all eyes on (MAIA) this morning. I know it’s still early but I wanted to make sure you saw (MAIA) and why it's topping our watchlist this morning.  I’ll check back in with you shortly. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired by TD Media LLC for a period beginning on 01/12/2025 and ending on 01/13/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (MAIA:US) via digital communications. These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/maia/

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice